
SQZ Biotechnologies (NYSE:SQZ) received Fast Track Designation from he U.S. Food and Drug Administration (FDA) for its lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.
SQZ-PBMC-HPV-101 is currently being investigated in the Phase 1/2 clinical study.